Colorectal Cancer and Therapy Response: a Focus on the Main Mechanisms Involved

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Aug 4

PMID 37538108

Authors

Sara Tirendi

Barbara Marengo

Cinzia Domenicotti

Anna M Bassi

Vanessa Almonti

Stefania Vernazza

Affiliations

Soon will be listed here.

Abstract

Introduction: The latest GLOBOCAN 2021 reports that colorectal cancer (CRC) is the second leading cause of cancer-related death worldwide. Most CRC cases are sporadic and associated with several risk factors, including lifestyle habits, gut dysbiosis, chronic inflammation, and oxidative stress.

Aim: To summarize the biology of CRC and discuss current therapeutic interventions designed to counteract CRC development and to overcome chemoresistance.

Methods: Literature searches were conducted using PubMed and focusing the attention on the keywords such as "Current treatment of CRC" or "chemoresistance and CRC" or "oxidative stress and CRC" or "novel drug delivery approaches in cancer" or "immunotherapy in CRC" or "gut microbiota in CRC" or "systematic review and meta-analysis of randomized controlled trials" or "CSCs and CRC". The citations included in the search ranged from September 1988 to December 2022. An additional search was carried out using the clinical trial database.

Results: Rounds of adjuvant therapies, including radiotherapy, chemotherapy, and immunotherapy are commonly planned to reduce cancer recurrence after surgery (stage II and stage III CRC patients) and to improve overall survival (stage IV). 5-fluorouracil-based chemotherapy in combination with other cytotoxic drugs, is the mainstay to treat CRC. However, the onset of the inherent or acquired resistance and the presence of chemoresistant cancer stem cells drastically reduce the efficacy. On the other hand, the genetic-molecular heterogeneity of CRC often precludes also the efficacy of new therapeutic approaches such as immunotherapies. Therefore, the CRC complexity made of natural or acquired multidrug resistance has made it necessary the search for new druggable targets and new delivery systems.

Conclusion: Further knowledge of the underlying CRC mechanisms and a comprehensive overview of current therapeutic opportunities can provide the basis for identifying pharmacological and biological barriers that render therapies ineffective and for identifying new potential biomarkers and therapeutic targets for advanced and aggressive CRC.

Citing Articles

Promising Cellular Immunotherapy for Colorectal Cancer Using Classical Dendritic Cells and Natural Killer T Cells.

Singer M, Valerin J, Zhang Z, Zhang Z, Dayyani F, Yaghmai V Cells. 2025; 14(3).

PMID: 39936958 PMC: 11817869. DOI: 10.3390/cells14030166.

An Investigation of the Anticancer Mechanism of L. Extract Against Colorectal Cancer by Integrating a Network Pharmacological Analysis and Experimental Validation.

Jeong M, Chun J, Park S, Yeo H, Na S, Ha I Plants (Basel). 2025; 14(2.

PMID: 39861616 PMC: 11768342. DOI: 10.3390/plants14020263.

Cannabigerol Treatment Shows Antiproliferative Activity and Causes Apoptosis of Human Colorectal Cancer Cells.

Park J, Hwang Y, Na H, Kim D, Lee H, Kwon T J Pharmacopuncture. 2025; 27(4):332-339.

PMID: 39741567 PMC: 11656058. DOI: 10.3831/KPI.2024.27.4.332.

Bcl‑xL‑specific BH3 mimetic A‑1331852 suppresses proliferation of fluorouracil‑resistant colorectal cancer cells by inducing apoptosis.

Kato A, Takahashi H, Asai H, Uehara S, Harata S, Fujii Y Oncol Rep. 2024; 53(2.

PMID: 39717947 PMC: 11718432. DOI: 10.3892/or.2024.8859.

Circ_0006174 Upregulates IGF1R to Enhance Radioresistance and Tumorigenesis in Colorectal Cancer via miR-940 Suppression.

Zhang X, Fang F, Zhang J, Zhang S, Li H, Li B Appl Biochem Biotechnol. 2024; 197(1):497-517.

PMID: 39172343 DOI: 10.1007/s12010-024-05028-9.

References

Sanchez-Lopez E, Guerra M, Dias-Ferreira J, Lopez-Machado A, Ettcheto M, Cano A . Current Applications of Nanoemulsions in Cancer Therapeutics. Nanomaterials (Basel). 2019; 9(6). PMC: 6632105. DOI: 10.3390/nano9060821. View

Lu C, Shervington A . Chemoresistance in gliomas. Mol Cell Biochem. 2008; 312(1-2):71-80. DOI: 10.1007/s11010-008-9722-8. View

Mross K, Frost A, Steinbild S, Hedbom S, Buchert M, Fasol U . A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res. 2012; 18(9):2658-67. DOI: 10.1158/1078-0432.CCR-11-1900. View

Forouzesh D, Moran G . Mammalian dihydropyrimidine dehydrogenase. Arch Biochem Biophys. 2021; 714:109066. DOI: 10.1016/j.abb.2021.109066. View

Zhu X, Tian X, Ji L, Zhang X, Cao Y, Shen C . A tumor microenvironment-specific gene expression signature predicts chemotherapy resistance in colorectal cancer patients. NPJ Precis Oncol. 2021; 5(1):7. PMC: 7881244. DOI: 10.1038/s41698-021-00142-x. View

Wculek S, Cueto F, Mujal A, Melero I, Krummel M, Sancho D . Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2019; 20(1):7-24. DOI: 10.1038/s41577-019-0210-z. View

Bastos D, Ribeiro S, de Freitas D, Hoff P . Combination therapy in high-risk stage II or stage III colon cancer: current practice and future prospects. Ther Adv Med Oncol. 2011; 2(4):261-72. PMC: 3126021. DOI: 10.1177/1758834010367905. View

Vogel J, Felder S, Bhama A, Hawkins A, Langenfeld S, Shaffer V . The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Colon Cancer. Dis Colon Rectum. 2021; 65(2):148-177. DOI: 10.1097/DCR.0000000000002323. View

Vernazza S, Dellacasa E, Tirendi S, Pastorino L, Bassi A . Lipoperoxide Nanoemulsion as Adjuvant in Cisplatin Cancer Therapy: In Vitro Study on Human Colon Adenocarcinoma DLD-1 Cells. Nanomaterials (Basel). 2021; 11(6). PMC: 8224288. DOI: 10.3390/nano11061365. View

10.

Wong C, Xu J, Bian X, Wu J, Kang W, Qian Y . In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance. Gastroenterology. 2020; 159(6):2163-2180.e6. DOI: 10.1053/j.gastro.2020.08.016. View

11.

Jelic M, Mandic A, Maricic S, Srdjenovic B . Oxidative stress and its role in cancer. J Cancer Res Ther. 2021; 17(1):22-28. DOI: 10.4103/jcrt.JCRT_862_16. View

12.

Arai H, Battaglin F, Wang J, Lo J, Soni S, Zhang W . Molecular insight of regorafenib treatment for colorectal cancer. Cancer Treat Rev. 2019; 81:101912. PMC: 7491975. DOI: 10.1016/j.ctrv.2019.101912. View

13.

Erez A, DeBerardinis R . Metabolic dysregulation in monogenic disorders and cancer - finding method in madness. Nat Rev Cancer. 2015; 15(7):440-8. DOI: 10.1038/nrc3949. View

14.

Chen C, Bai L, Cao F, Wang S, He H, Song M . Targeting LIN28B reprograms tumor glucose metabolism and acidic microenvironment to suppress cancer stemness and metastasis. Oncogene. 2019; 38(23):4527-4539. DOI: 10.1038/s41388-019-0735-4. View

15.

Blondy S, David V, Verdier M, Mathonnet M, Perraud A, Christou N . 5-Fluorouracil resistance mechanisms in colorectal cancer: From classical pathways to promising processes. Cancer Sci. 2020; 111(9):3142-3154. PMC: 7469786. DOI: 10.1111/cas.14532. View

16.

Walcher L, Kistenmacher A, Suo H, Kitte R, Dluczek S, Strauss A . Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies. Front Immunol. 2020; 11:1280. PMC: 7426526. DOI: 10.3389/fimmu.2020.01280. View

17.

Zhao J . Cancer stem cells and chemoresistance: The smartest survives the raid. Pharmacol Ther. 2016; 160:145-58. PMC: 4808328. DOI: 10.1016/j.pharmthera.2016.02.008. View

18.

Berghella A, Aureli A, Canossi A, Del Beato T, Colanardi A, Pellegrini P . Redox, immune and genetic biomarker system for personalized treatments in colorectal cancer. World J Gastrointest Oncol. 2019; 11(2):117-138. PMC: 6379753. DOI: 10.4251/wjgo.v11.i2.117. View

19.

Ducreux M, Bouche O, Pignon J, Mousseau M, Raoul J, Cassan P . Randomised trial comparing three different schedules of infusional 5FU and raltitrexed alone as first-line therapy in metastatic colorectal cancer. Final results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 trial. Oncology. 2006; 70(3):222-30. DOI: 10.1159/000094357. View

20.

Sun W, Li J, Zhou L, Han J, Liu R, Zhang H . The c-Myc/miR-27b-3p/ATG10 regulatory axis regulates chemoresistance in colorectal cancer. Theranostics. 2020; 10(5):1981-1996. PMC: 7019154. DOI: 10.7150/thno.37621. View